3M and Takeda Pharmaceutical Company Limited have entered into an exclusive co-development and joint marketing agreement to collaborate on a potential topical treatment for cervical high-risk human papillomavirus (HPV) infection and cervical dysplasia.
The compound is currently in early stage (Phase I) clinical testing. Under the terms of this agreement, 3M and Takeda will share further costs of development.
Upon successful clinical development and regulatory approvals, the companies will jointly commercialize in the United States and European Union. Takeda will retain exclusive rights in Japan and certain Asian countries, and 3M will have exclusive commercialization rights in all other areas of the world, the release said.
The compound is part of the family of immune response modifier (IRM) molecules developed by 3M Pharmaceuticals. IRMs act in a novel way to stimulate the human body's immune system to fight virus-infected cells and tumour cells. 3M currently markets Aldara (imiquimod) Cream 5%, the first topical IRM to be marketed globally, for the treatment of actinic keratosis, primary superficial basal cell carcinoma, and external genital and perianal warts.
"This is an excellent opportunity to advance the development and commercialization of a new pharmacological treatment for HPV infection in women at risk for cervical cancer," said Barry Labinger, division vice president, 3M Pharmaceuticals.
HPV can infect the skin surface in any part of the body and is one of the most common sexually transmitted viruses. More than 100 types of HPV exist, including over 20 high-risk types that may cause abnormal cervical Pap smears.